SUZANNE O'BRIEN: Open Payments
NPI 1730735564 · PARAMUS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,414 in 167 payments from 14 companies in 2025. Trend: 2023 $441 · 2024 $1,718 · 2025 $2,414
Food & beverage: $2,414
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 21 | $511 |
| Neurocrine BioSciences, Inc. | 23 | $334 |
| ABBVIE INC. | 39 | $333 |
| Otsuka America Pharmaceutical, Inc. | 22 | $295 |
| E.R. Squibb & Sons, L.L.C. | 20 | $223 |
| Teva Pharmaceuticals USA, Inc. | 10 | $171 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $157 |
| Vanda Pharmaceuticals Inc. | 8 | $139 |
| Lundbeck LLC | 5 | $92 |
| Janssen Pharmaceuticals, Inc | 3 | $53 |
Products named: INGREZZA, VRAYLAR, ARISTADA, REXULTI, COBENFY, CAPLYTA, LYBALVI, FANAPT.
Industry payments across NJ — which companies pay providers there.
